KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Net Cash Flow (2016 - 2025)

BeOne Medicines (ONC) has disclosed Net Cash Flow for 11 consecutive years, with $379.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow rose 1750.17% to $379.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.8 billion, a 466.06% increase, with the full-year FY2025 number at $851.4 million, up 271.82% from a year prior.
  • Net Cash Flow was $379.0 million for Q4 2025 at BeOne Medicines, down from $1.3 billion in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $3.4 billion in Q4 2021 to a low of -$398.5 million in Q3 2021.
  • A 5-year average of $179.1 million and a median of -$48.7 million in 2022 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: skyrocketed 3721.64% in 2021, then tumbled 815.09% in 2023.
  • BeOne Medicines' Net Cash Flow stood at $3.4 billion in 2021, then tumbled by 111.51% to -$390.0 million in 2022, then soared by 116.11% to $62.8 million in 2023, then tumbled by 136.56% to -$23.0 million in 2024, then surged by 1750.17% to $379.0 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's Net Cash Flow are $379.0 million (Q4 2025), $1.3 billion (Q3 2025), and $232.0 million (Q2 2025).